AllyxThera
  • Home
  • About Us
  • Our Science
  • News and Events
  • Careers
  • Contact
Select Page

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

by Tim Siegert | Oct 30, 2023 | Press Release | 0 comments

Recent Posts

  • Allyx Therapeutics Announces Successful Completion of  Two Additional Studies of Lead Candidate ALX-001
  • Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
  • Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
  • Neurology Live: Synapse-Targeting Agent ALX-001 Ready for Phase 2 Following Early-Stage ProgressNeurology Live: on First Patient Treated
  • Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

Menu

  • Home
  • About Us
  • Our Science
  • News and Events
  • Careers
  • Contact

Contact

Allyx Therapeutics, Inc.
555 Long Wharf Drive
Floor 11
New Haven, CT 06511

info@allyxthera.com

Social

Copyright © 2026Allyx Therapeutics, Inc.